Medrx Co., Ltd. (JP:4586)

:4586

4586

Medrx Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4586 full AI Analyst Report?

Medrx Co., Ltd. (4586) Price & Analysis

0 Followers

4586 Stock Chart & Stats

¥113.00

¥2.00(2.50%)

At close: Jan 08 4:00 PM EST

¥113.00

¥2.00(2.50%)

Day’s Range― - ―

52-Week Range¥58.00 - ¥225.00

Previous CloseN/A

Volume596.00K

Average Volume (3M)2.57M

Market Cap

¥5.05B

Enterprise Value¥3.35B

Total Cash (Recent Filing)¥1.67B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.47

Next Earnings

May 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.60

Shares Outstanding59,365,100

10 Day Avg. Volume1,116,360

30 Day Avg. Volume2,574,156

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)2.83

Price to Sales (P/S)45.31

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained 85–90% gross margins indicate advantaged unit economics or high-value product mix. This structural margin cushion supports investments in R&D and commercialization, allowing the company to absorb SG&A and development spend and still achieve operating leverage if revenues scale.

Zero DebtA debt-free balance sheet materially reduces solvency risk and interest burden, preserving strategic optionality. Over 2–6 months, this structural conservatism lowers bankruptcy risk and makes the company better positioned to raise equity or negotiate partnerships without restrictive covenants.

2025 Revenue ReboundA large, durable revenue uptick suggests improving commercial traction or successful product/market moves. If sustained, this creates a platform for fixed-cost absorption and margin expansion, making future R&D and scale investments more productive and improving long-term viability.

Bears Say

Persistently Deep LossesChronic operating and net losses erode shareholder equity and signal the core business is not profitable at scale today. Over months, continued losses threaten the equity base, reduce management flexibility, and force reliance on dilutive funding or partnerships absent a clear path to profitability.

Consistent Negative Cash FlowRecurring negative operating and free cash flow means the business is not self-sustaining and must access external capital to operate. This structural cash burn increases dilution risk, curtails long-term R&D or commercial spending without financing, and heightens vulnerability in tighter capital markets.

Expenses Outpacing RevenueExtremely negative net margins despite high gross profit indicate operating expenses or one-time charges dwarf revenue. Without durable cost control or much higher revenue scale, the business cannot translate gross margin into profit, undermining long-term sustainability.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥58.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥5.05B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 24 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥2.6 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.6.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 59,365,100 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥2.6 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.885%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.